IO Frontiers World 2019

Speakers

Loading
Mark Gardner

Mark Gardner

CEO, OmniSeq, Inc

Mark Gardner is the Chief Executive Officer of OmniSeq Precision Medicine Technology and a member of our Board of Directors. Prior to joining OmniSeq, Mark spent over twelve years in various executive roles at Thermo Fisher Scientific (previously Life Technologies).

Most recently, Mark was the Vice President and General Manager of the Ion Torrent business unit at Thermo Fisher. Prior to Thermo Fisher, Mark was a Six Sigma Master Black Belt at General Electric, an entrepreneur at two start-up companies, a management consultant at McKinsey and Company, and a Navy Pilot. 

Mark is responsible for financing the company, and managing the executive team.

Mark earned an MBA in Finance with Palmer Scholar Distinction from the Wharton School of Business, an MA in National Security Studies from Georgetown University, and a BS with Distinction from the US Naval Academy.

 

Sessions
  • "Great venue to solidify and harmonize on the current challenges facing this sector - in real time. The caliber of the speakers and session contents was premier. “
    Dolores Baksh
    Innovation Leader, GE Healthcare
  • “A great event to learn about the hurdles that are needed to be overcome to get through the clinic.”
    Devin Bridgen
    Scientist, strategic partnerships, SQZ Biotech
  • "It was a great opportunity to share current data and thinking about the development of therapeutics directed at modulating the immune response to cancer."
    Lance Leopold
    Vice President, Head of Oncology Development, Incyte Corporation
  • "Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field."
    Dr James Trager
    Vice President, Research & Product Development, Dendreon
  • “In the rapidly moving Advanced Therapy market, Phacilitate remains one of the premier events.”
    David James
    CEO, Scinogy